Full Breakdown
Health Canada Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
6/25/2026, 11:06:32 AM
Regulatory Approval of Zepbound for OSA
Health Canada approved tirzepatide (Zepbound) on June 11 for adults with obesity (BMI >= 30) and obstructive sleep apnea, the first GLP-1 drug cleared for this use in Canada.
Obstructive Sleep Apnea, Obesity, and GLP-1 Therapy
OSA arises from airway collapse during sleep. Obesity adds fatty tissue around the airway, worsening OSA; weight loss improves it. GLP-1 agonists such as tirzepatide suppress appetite, promoting weight loss. Eli Lilly markets tirzepatide as Zepbound (weight management) and Mounjaro (diabetes); competitors include Novo Nordisk’s semaglutide (Ozempic, Wegovy).
Key Figures & Groups
Dr. Mandeep Singh, sleep-science clinician at University Health Network, analyzed the trial data. Health Canada spokesperson Marie-Pier Burelle announced the approval. Eli Lilly manufactures Zepbound.
Clinical Trial Data and Statistics
Phase 3 trials enrolled obese adults (BMI >= 30) with OSA. Without CPAP, tirzepatide reduced breathing interruptions by 25 events per hour versus five with placebo; with CPAP, the reduction was 29 versus six. OSA severity is mild (5-14), moderate (15-30), severe (>30) events/hour, so a 25-29-event drop can move many patients from severe to a lower category. Three million Canadians use GLP-1 drugs. Side effects are nausea, vomiting, diarrhea, constipation; rare serious events include pancreatitis, bowel obstruction, gallstones.
Potential Impact
Zepbound adds an option that may lower OSA severity and reduce CPAP dependence, though it is not a direct CPAP substitute. Expanding treatment choices could lessen OSA-related cardiovascular complications.
Official Statements & Responses
Health Canada recommends tirzepatide injections with a reduced-calorie diet and increased activity, and warns patients not to stop CPAP without a doctor’s advice. Dr. Singh said weight loss improves OSA and that the observed reduction in breathing events is clinically meaningful.
Criticism & Limitations
The trials enrolled obese participants, so efficacy in non-obese OSA patients is unknown. It is unclear whether benefits arise mainly from weight loss or a direct airway effect of tirzepatide. Anecdotal reports of OSA improvement with other GLP-1 drugs lack systematic evidence; rare serious side effects need ongoing monitoring.
Conflicting Reports & Gaps
Sources note no research on OSA improvement with GLP-1 agents other than tirzepatide and call for studies that separate weight-loss effects from direct drug actions. Long-term real-world effectiveness data are missing.
Verbatim Quotes
- “Patients taking Zepbound should not stop using their CPAP machine without a doctor’s guidance,” — Marie-Pier Burelle, Health Canada spokesperson
- “A reduction of 25–29 events per hour would represent a meaningful change, potentially shifting someone from severe into a lower severity category depending on where they started,” — Dr. Mandeep Singh, University Health Network
- “I think that’s a welcome step towards offering, you know, another option for patients who have obstructive sleep apnea,” — Dr. Mandeep Singh
What’s Next
Ongoing studies will test tirzepatide in non-obese OSA patients and aim to isolate any direct airway effect. Pharmacovigilance will monitor rare adverse events, and guidelines will consider Zepbound as an adjunct therapy.
